Selected research
Industry Research
Pharma Contract Service Industry Research Report 2026
Market perspective
The global Pharma Contract Service market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Pharma Contract Service market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Pharma Contract Service market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Pharma Contract Service market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Pharma Contract Service include ICON PLC, IQVIA, PPD, Eurofins Scientific, WuXi AppTec, Labcorp Drug Development, Syneos Health, Parexel and Medpace, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Pharma Contract Service market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Pharma Contract Service.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Pharma Contract Service Market by Company
ICON PLC
IQVIA
PPD
Eurofins Scientific
WuXi AppTec
Labcorp Drug Development
Syneos Health
Parexel
Medpace
Charles River
Lonza
Aldevron
Catalent
Pharma Contract Service Segment by Type
Contract Research Organization (CRO)
Contract Development and Manufacruring Organization (CDMO)
Contract Manufacturing Organization (CMO)
Pharma Contract Service Segment by Application
Pharmaceutical Company
Biotechnology Company
Generic Company
Pharma Contract Service Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pharma Contract Service market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Pharma Contract Service and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pharma Contract Service.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Pharma Contract Service companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Contract Research Organization (CRO)
- Contract Development and Manufacruring Organization (CDMO)
- Contract Manufacturing Organization (CMO)
Applications
- Pharmaceutical Company
- Biotechnology Company
- Generic Company
Companies covered
- ICON PLC
- IQVIA
- PPD
- Eurofins Scientific
- WuXi AppTec
- Labcorp Drug Development
- Syneos Health
- Parexel
- Medpace
- Charles River
- Lonza
- Aldevron
- Catalent
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Pharma Contract Service by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Contract Research Organization (CRO)
- 2.2.3 Contract Development and Manufacruring Organization (CDMO)
- 2.2.4 Contract Manufacturing Organization (CMO)
- 2.3 Pharma Contract Service by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Pharmaceutical Company
- 2.3.3 Biotechnology Company
- 2.3.4 Generic Company
- 2.4 Assumptions and Limitations
3 Pharma Contract Service Breakdown Data by Type
- 3.1 Global Pharma Contract Service Historic Market Size by Type (2021-2026)
- 3.2 Global Pharma Contract Service Forecasted Market Size by Type (2027-2032)
4 Pharma Contract Service Breakdown Data by Application
- 4.1 Global Pharma Contract Service Historic Market Size by Application (2021-2026)
- 4.2 Global Pharma Contract Service Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Pharma Contract Service Market Perspective (2021-2032)
- 5.2 Global Pharma Contract Service Growth Trends by Region
- 5.2.1 Global Pharma Contract Service Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Pharma Contract Service Historic Market Size by Region (2021-2026)
- 5.2.3 Pharma Contract Service Forecasted Market Size by Region (2027-2032)
- 5.3 Pharma Contract Service Market Dynamics
- 5.3.1 Pharma Contract Service Industry Trends
- 5.3.2 Pharma Contract Service Market Drivers
- 5.3.3 Pharma Contract Service Market Challenges
- 5.3.4 Pharma Contract Service Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Pharma Contract Service Players by Revenue
- 6.1.1 Global Top Pharma Contract Service Players by Revenue (2021-2026)
- 6.1.2 Global Pharma Contract Service Revenue Market Share by Players (2021-2026)
- 6.2 Global Pharma Contract Service Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Pharma Contract Service Head Office and Area Served
- 6.4 Global Pharma Contract Service Players, Product Type & Application
- 6.5 Global Pharma Contract Service Manufacturers Established Date
- 6.6 Global Pharma Contract Service Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Pharma Contract Service Market Size (2021-2032)
- 7.2 North America Pharma Contract Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Pharma Contract Service Market Size by Country (2021-2026)
- 7.4 North America Pharma Contract Service Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Pharma Contract Service Market Size (2021-2032)
- 8.2 Europe Pharma Contract Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Pharma Contract Service Market Size by Country (2021-2026)
- 8.4 Europe Pharma Contract Service Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Pharma Contract Service Market Size (2021-2032)
- 9.2 Asia-Pacific Pharma Contract Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Pharma Contract Service Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Pharma Contract Service Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Pharma Contract Service Market Size (2021-2032)
- 10.2 South America Pharma Contract Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Pharma Contract Service Market Size by Country (2021-2026)
- 10.4 South America Pharma Contract Service Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Pharma Contract Service Market Size (2021-2032)
- 11.2 Middle East & Africa Pharma Contract Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Pharma Contract Service Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Pharma Contract Service Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 ICON PLC
- 12.1.1 ICON PLC Company Information
- 12.1.2 ICON PLC Business Overview
- 12.1.3 ICON PLC Revenue in Pharma Contract Service Business (2021-2026)
- 12.1.4 ICON PLC Pharma Contract Service Product Portfolio
- 12.1.5 ICON PLC Recent Developments
- 12.2 IQVIA
- 12.2.1 IQVIA Company Information
- 12.2.2 IQVIA Business Overview
- 12.2.3 IQVIA Revenue in Pharma Contract Service Business (2021-2026)
- 12.2.4 IQVIA Pharma Contract Service Product Portfolio
- 12.2.5 IQVIA Recent Developments
- 12.3 PPD
- 12.3.1 PPD Company Information
- 12.3.2 PPD Business Overview
- 12.3.3 PPD Revenue in Pharma Contract Service Business (2021-2026)
- 12.3.4 PPD Pharma Contract Service Product Portfolio
- 12.3.5 PPD Recent Developments
- 12.4 Eurofins Scientific
- 12.4.1 Eurofins Scientific Company Information
- 12.4.2 Eurofins Scientific Business Overview
- 12.4.3 Eurofins Scientific Revenue in Pharma Contract Service Business (2021-2026)
- 12.4.4 Eurofins Scientific Pharma Contract Service Product Portfolio
- 12.4.5 Eurofins Scientific Recent Developments
- 12.5 WuXi AppTec
- 12.5.1 WuXi AppTec Company Information
- 12.5.2 WuXi AppTec Business Overview
- 12.5.3 WuXi AppTec Revenue in Pharma Contract Service Business (2021-2026)
- 12.5.4 WuXi AppTec Pharma Contract Service Product Portfolio
- 12.5.5 WuXi AppTec Recent Developments
- 12.6 Labcorp Drug Development
- 12.6.1 Labcorp Drug Development Company Information
- 12.6.2 Labcorp Drug Development Business Overview
- 12.6.3 Labcorp Drug Development Revenue in Pharma Contract Service Business (2021-2026)
- 12.6.4 Labcorp Drug Development Pharma Contract Service Product Portfolio
- 12.6.5 Labcorp Drug Development Recent Developments
- 12.7 Syneos Health
- 12.7.1 Syneos Health Company Information
- 12.7.2 Syneos Health Business Overview
- 12.7.3 Syneos Health Revenue in Pharma Contract Service Business (2021-2026)
- 12.7.4 Syneos Health Pharma Contract Service Product Portfolio
- 12.7.5 Syneos Health Recent Developments
- 12.8 Parexel
- 12.8.1 Parexel Company Information
- 12.8.2 Parexel Business Overview
- 12.8.3 Parexel Revenue in Pharma Contract Service Business (2021-2026)
- 12.8.4 Parexel Pharma Contract Service Product Portfolio
- 12.8.5 Parexel Recent Developments
- 12.9 Medpace
- 12.9.1 Medpace Company Information
- 12.9.2 Medpace Business Overview
- 12.9.3 Medpace Revenue in Pharma Contract Service Business (2021-2026)
- 12.9.4 Medpace Pharma Contract Service Product Portfolio
- 12.9.5 Medpace Recent Developments
- 12.10 Charles River
- 12.10.1 Charles River Company Information
- 12.10.2 Charles River Business Overview
- 12.10.3 Charles River Revenue in Pharma Contract Service Business (2021-2026)
- 12.10.4 Charles River Pharma Contract Service Product Portfolio
- 12.10.5 Charles River Recent Developments
- 12.11 Lonza
- 12.11.1 Lonza Company Information
- 12.11.2 Lonza Business Overview
- 12.11.3 Lonza Revenue in Pharma Contract Service Business (2021-2026)
- 12.11.4 Lonza Pharma Contract Service Product Portfolio
- 12.11.5 Lonza Recent Developments
- 12.12 Aldevron
- 12.12.1 Aldevron Company Information
- 12.12.2 Aldevron Business Overview
- 12.12.3 Aldevron Revenue in Pharma Contract Service Business (2021-2026)
- 12.12.4 Aldevron Pharma Contract Service Product Portfolio
- 12.12.5 Aldevron Recent Developments
- 12.13 Catalent
- 12.13.1 Catalent Company Information
- 12.13.2 Catalent Business Overview
- 12.13.3 Catalent Revenue in Pharma Contract Service Business (2021-2026)
- 12.13.4 Catalent Pharma Contract Service Product Portfolio
- 12.13.5 Catalent Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst